Free Trial
→ Now I look stupid. Real stupid... (From Porter & Company) (Ad) Buy ATRC Stock  Free ATRC Stock Alerts

AtriCure (ATRC) Financials

AtriCure logo
$32.08 -0.28 (-0.87%)
As of 04:00 PM Eastern
Compare
Annual Income Statements for AtriCure

Annual Income Statements for AtriCure

This table shows AtriCure's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders		 -16 -27 -33 -27 -21 -35 -48 50 -46 -30 -45
Consolidated Net Income / (Loss)		 -16 -27 -33 -27 -21 -35 -48 50 -46 -30 -45
Net Income / (Loss) Continuing Operations		 -16 -27 -33 -27 -21 -35 -48 50 -46 -30 -45
Total Pre-Tax Income 		-16 -27 -33 -27 -21 -35 -48 50 -46 -30 -44
Total Operating Income		 -16 -27 -31 -25 -17 -33 -44 55 -43 -27 -40
Total Gross Profit		 76 93 111 126 147 170 149 206 246 300 348
Total Revenue		 107 130 155 175 202 231 207 274 330 399 465
Operating Revenue		 107 130 155 175 202 231 207 274 330 399 465
Total Cost of Revenue		 32 37 44 49 55 60 57 68 84 99 118
Operating Cost of Revenue		 32 37 44 49 55 60 57 68 84 99 118
Total Operating Expenses		 92 120 142 151 164 203 194 151 289 327 388
Selling, General & Admin Expense		 74 94 106 117 130 167 151 205 231 253 291
Research & Development Expense		 19 26 36 34 35 41 43 49 57 74 96
Total Other Income / (Expense), net		 0.18 -0.46 -2.16 -1.90 -3.78 -1.87 -3.81 -4.82 -3.53 -3.16 -3.66
Interest Expense		 0.31 0.29 1.80 2.26 4.61 4.11 4.89 4.92 4.99 6.93 7.77
Interest & Investment Income		 0.10 0.19 0.23 0.23 1.01 2.40 1.10 0.47 1.99 3.79 4.43
Other Income / (Expense), net		 0.39 -0.35 -0.59 0.14 -0.18 -0.16 -0.02 -0.37 -0.54 -0.03 -0.33
Income Tax Expense		 0.03 0.04 0.04 0.01 0.23 0.20 0.11 0.19 0.27 0.59 1.02
Basic Earnings per Share		 ($0.61) ($0.97) ($1.05) ($0.83) ($0.62) ($0.94) ($1.14) $1.11 ($1.02) ($0.66) ($0.95)
Weighted Average Basic Shares Outstanding		 26.37M 28.06M 31.61M 32.39M 34.09M 37.59M 42.13M 45.07M 45.74M 46.31M 46.97M
Diluted Earnings per Share		 ($0.61) ($0.97) ($1.05) ($0.83) ($0.62) ($0.94) ($1.14) $1.09 ($1.02) ($0.66) ($0.95)
Weighted Average Diluted Shares Outstanding		 26.37M 28.06M 31.61M 32.39M 34.09M 37.59M 42.13M 46.04M 45.74M 46.31M 46.97M
Weighted Average Basic & Diluted Shares Outstanding		 26.37M 28.06M 31.61M 32.39M 34.09M 37.59M 42.13M 46.03M 93.14M 95.18M 48.88M

Quarterly Income Statements for AtriCure

This table shows AtriCure's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders		 -12 -4.17 -6.48 -5.12 -9.06 -9.79 -13 -8.01 -7.85 -16
Consolidated Net Income / (Loss)		 -12 -4.17 -6.48 -5.12 -9.06 -9.79 -13 -8.01 -7.85 -16
Net Income / (Loss) Continuing Operations		 -12 -4.17 -6.48 -5.12 -9.06 -9.79 -13 -8.01 -7.85 -16
Total Pre-Tax Income 		-12 -4.05 -6.40 -5.03 -9.01 -9.42 -13 -7.76 -7.53 -15
Total Operating Income		 -11 -4.14 -5.78 -4.14 -8.09 -8.67 -11 -7.17 -7.41 -15
Total Gross Profit		 62 65 70 77 74 80 81 87 87 93
Total Revenue		 83 88 93 101 98 107 109 116 116 124
Operating Revenue		 83 88 93 101 98 107 109 116 116 124
Total Cost of Revenue		 22 23 24 24 24 27 28 29 29 32
Operating Cost of Revenue		 22 23 24 24 24 27 28 29 29 32
Total Operating Expenses		 72 69 75 81 82 88 92 94 94 107
Selling, General & Admin Expense		 57 56 60 64 62 68 72 74 73 72
Research & Development Expense		 15 14 15 17 20 21 20 20 21 35
Total Other Income / (Expense), net		 -1.50 0.09 -0.62 -0.88 -0.92 -0.75 -2.17 -0.59 -0.13 -0.78
Interest Expense		 1.32 1.56 1.64 1.72 1.77 1.80 3.04 1.61 1.67 1.45
Interest & Investment Income		 0.37 1.43 0.88 0.96 0.92 1.04 0.95 1.00 1.28 1.20
Other Income / (Expense), net		 -0.55 0.22 0.15 -0.12 -0.06 0.01 -0.08 0.03 0.26 -0.53
Income Tax Expense		 0.05 0.12 0.08 0.09 0.05 0.37 0.18 0.25 0.32 0.27
Basic Earnings per Share		 ($0.27) ($0.10) ($0.14) ($0.11) ($0.20) ($0.21) ($0.28) ($0.17) ($0.17) ($0.33)
Weighted Average Basic Shares Outstanding		 45.82M 45.74M 46.11M 46.27M 46.41M 46.31M 46.72M 46.91M 47.11M 46.97M
Diluted Earnings per Share		 ($0.27) ($0.10) ($0.14) ($0.11) ($0.20) ($0.21) ($0.28) ($0.17) ($0.17) ($0.33)
Weighted Average Diluted Shares Outstanding		 45.82M 45.74M 46.11M 46.27M 46.41M 46.31M 46.72M 46.91M 47.11M 46.97M
Weighted Average Basic & Diluted Shares Outstanding		 - 93.14M 47.24M 47.35M 47.40M 95.18M 48.38M 48.70M 48.75M 48.88M

Annual Cash Flow Statements for AtriCure

This table details how cash moves in and out of AtriCure's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Change in Cash & Equivalents		 13 -4.62 0.44 -2.40 10 -3.75 13 1.71 14 26 38
Net Cash From Operating Activities		 -22 -7.84 -15 -8.94 -4.17 -16 -20 -14 -22 4.48 12
Net Cash From Continuing Operating Activities		 -22 -7.84 -15 -8.94 -4.17 -16 -20 -14 -22 4.48 12
Net Income / (Loss) Continuing Operations		 -16 -27 -33 -27 -21 -35 -48 50 -46 -30 -45
Consolidated Net Income / (Loss)		 -16 -27 -33 -27 -21 -35 -48 50 -46 -30 -45
Depreciation Expense		 3.35 4.98 7.66 7.76 7.24 7.42 7.87 7.53 8.06 9.46 11
Amortization Expense		 2.03 1.94 1.99 1.66 1.66 1.40 3.43 6.15 5.64 6.47 8.10
Non-Cash Adjustments To Reconcile Net Income		 8.20 9.85 13 15 17 18 23 110 29 36 54
Changes in Operating Assets and Liabilities, net		 -19 2.60 -4.11 -6.08 -8.66 -7.41 -5.65 -188 -18 -17 -16
Net Cash From Investing Activities		 -31 -11 -12 3.76 -85 -2.15 -156 24 44 22 30
Net Cash From Continuing Investing Activities		 -31 -11 -12 3.76 -85 -2.15 -156 24 44 22 30
Purchase of Property, Plant & Equipment		 -5.51 -13 -7.69 -6.38 -6.21 -12 -5.26 -9.75 -17 -12 -11
Acquisitions		 0.00 -7.58 - 0.00 0.00 -17 - 0.00 0.00 -30 -12
Purchase of Investments		 -41 -20 -29 -16 -107 -73 -227 -173 -25 0.00 0.00
Sale of Property, Plant & Equipment		 0.08 0.00 0.00 0.00 0.01 0.04 - - 0.00 0.00 0.03
Sale and/or Maturity of Investments		 20 41 24 27 27 100 75 206 86 64 54
Net Cash From Financing Activities		 66 14 28 2.76 100 14 189 -7.64 -7.06 -0.03 -3.60
Net Cash From Continuing Financing Activities		 66 14 28 2.76 100 14 189 -7.64 -7.06 -0.03 -3.60
Repayment of Debt		 -6.56 -0.33 -0.56 -0.05 -2.89 -0.33 -0.70 -6.99 -0.90 -1.05 -64
Issuance of Debt		 0.00 0.00 25 0.00 17 20 0.00 5.00 0.00 0.00 61
Issuance of Common Equity		 67 1.54 1.62 2.11 85 2.66 192 4.18 4.23 5.26 5.06
Other Financing Activities, net		 5.28 13 1.64 0.70 0.43 -7.96 -2.19 -9.84 -10 -4.24 -5.93
Effect of Exchange Rate Changes		 -0.16 -0.24 -0.05 0.02 -0.18 -0.16 0.14 -0.37 -0.36 -0.06 -0.42
Cash Interest Paid		 0.12 0.23 1.51 2.00 3.87 3.72 4.37 4.22 4.27 6.38 5.95
Cash Income Taxes Paid		 0.15 0.02 0.03 0.04 0.07 0.26 0.22 0.19 0.19 0.40 0.62

Quarterly Cash Flow Statements for AtriCure

This table details how cash moves in and out of AtriCure's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents		 -5.73 9.28 19 -10 13 3.71 -19 41 24 -7.61
Net Cash From Operating Activities		 -1.78 0.05 -4.08 3.01 1.52 4.03 -21 7.38 20 5.84
Net Cash From Continuing Operating Activities		 -1.78 0.05 -4.08 3.01 1.52 4.03 -21 7.38 20 5.84
Net Income / (Loss) Continuing Operations		 -12 -4.17 -6.48 -5.12 -9.06 -9.79 -13 -8.01 -7.85 -16
Consolidated Net Income / (Loss)		 -12 -4.17 -6.48 -5.12 -9.06 -9.79 -13 -8.01 -7.85 -16
Depreciation Expense		 2.02 2.18 2.21 2.36 2.41 2.48 2.59 2.64 3.04 2.94
Amortization Expense		 1.39 1.07 1.03 1.47 1.99 1.99 2.15 1.95 2.01 2.00
Non-Cash Adjustments To Reconcile Net Income		 7.00 7.20 8.76 9.00 8.66 9.31 11 10 10 22
Changes in Operating Assets and Liabilities, net		 0.08 -6.23 -9.60 -4.69 -2.48 0.04 -23 0.41 12 -5.93
Net Cash From Investing Activities		 -3.24 7.00 29 -16 12 -2.79 9.64 31 4.39 -15
Net Cash From Continuing Investing Activities		 -3.24 7.00 29 -16 12 -2.79 9.64 31 4.39 -15
Purchase of Property, Plant & Equipment		 -5.15 -4.17 -2.50 -3.08 -3.63 -2.79 -2.77 -2.38 -3.61 -2.69
Acquisitions		 - - - - - - - - - -12
Net Cash From Financing Activities		 -0.41 1.98 -5.52 2.99 0.13 2.36 -7.86 2.85 -0.33 1.74
Net Cash From Continuing Financing Activities		 -0.41 1.98 -5.52 2.99 0.13 2.36 -7.86 2.85 -0.33 1.74
Repayment of Debt		 -0.23 -0.24 -0.30 -0.24 -0.25 -0.26 -63 -0.41 -0.34 -0.28
Other Financing Activities, net		 -0.18 -2.01 -5.22 3.24 0.38 -2.64 -6.15 3.26 0.00 -3.05
Effect of Exchange Rate Changes		 -0.31 0.25 0.03 -0.03 -0.17 0.11 -0.11 -0.06 0.24 -0.50
Cash Interest Paid		 1.13 1.34 1.49 1.59 1.64 1.66 0.73 1.45 1.43 2.35
Cash Income Taxes Paid		 0.00 0.06 -0.01 0.17 0.07 0.17 0.02 0.49 0.07 0.04

Annual Balance Sheets for AtriCure

This table presents AtriCure's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Total Assets		 158 273 276 268 357 558 715 615 585 614 609
Total Current Assets		 94 75 86 82 175 143 307 196 215 266 268
Cash & Equivalents		 28 24 24 22 32 28 42 44 58 84 123
Short-Term Investments		 31 11 20 13 92 53 202 75 63 53 0.00
Accounts Receivable		 18 19 21 23 25 28 23 33 43 53 60
Inventories, net		 14 18 18 22 22 29 35 39 46 68 75
Prepaid Expenses		 - - - 2.27 2.59 3.90 4.35 5.00 5.48 8.56 9.43
Plant, Property, & Equipment, net		 12 31 30 29 27 33 28 0.00 39 0.00 0.00
Total Noncurrent Assets		 53 167 161 157 155 382 380 419 331 348 342
Goodwill		 35 105 105 105 105 235 235 235 235 235 235
Intangible Assets		 8.88 54 52 51 49 130 128 43 39 64 56
Other Noncurrent Operating Assets		 0.19 0.32 0.32 0.68 0.50 4.74 2.35 37 5.77 49 50
Total Liabilities & Shareholders' Equity		 158 273 276 268 357 558 715 615 585 614 609
Total Liabilities		 26 86 108 107 107 311 302 132 129 148 148
Total Current Liabilities		 26 32 29 32 40 50 49 56 58 75 73
Short-Term Debt		 - 0.45 1.69 - - - - - 5.47 2.53 2.81
Accounts Payable		 7.62 13 11 12 9.66 15 13 19 20 27 25
Accrued Expenses		 14 18 16 19 26 33 28 36 33 45 46
Total Noncurrent Liabilities		 0.22 55 79 75 67 261 253 75 70 73 75
Long-Term Debt		 - 0.00 24 24 36 60 53 60 57 61 62
Other Noncurrent Operating Liabilities		 0.15 41 42 38 19 189 189 15 4.32 13 13
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 133 187 168 161 249 247 412 484 457 466 461
Total Preferred & Common Equity		 133 187 168 161 249 247 412 484 457 466 461
Total Common Equity		 133 187 168 161 249 247 412 484 457 466 461
Common Stock		 271 353 368 387 497 530 742 765 787 824 864
Retained Earnings		 -138 -166 -199 -226 -247 -282 -330 -280 -327 -357 -402
Accumulated Other Comprehensive Income / (Loss)		 -0.35 -0.61 -0.47 0.03 -0.20 -0.16 0.31 -0.95 -4.10 -0.99 -1.04

Quarterly Balance Sheets for AtriCure

This table presents AtriCure's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets		 583 594 600 592 597 615
Total Current Assets		 238 238 253 245 253 269
Cash & Equivalents		 77 67 81 65 106 130
Short-Term Investments		 59 60 52 41 7.99 0.00
Accounts Receivable		 46 48 52 55 56 55
Inventories, net		 49 55 62 72 74 77
Prepaid Expenses		 7.96 7.18 6.28 12 9.61 7.50
Plant, Property, & Equipment, net		 40 41 41 42 42 44
Total Noncurrent Assets		 305 316 306 304 302 302
Goodwill		 235 235 235 235 235 235
Intangible Assets		 39 67 66 62 60 58
Other Noncurrent Operating Assets		 6.23 5.89 5.69 7.46 7.23 9.11
Total Liabilities & Shareholders' Equity		 583 594 600 592 597 615
Total Liabilities		 128 132 137 135 135 150
Total Current Liabilities		 62 71 83 61 61 74
Accounts Payable		 24 24 25 29 27 32
Accrued Expenses		 28 32 37 30 32 40
Other Current Liabilities		 11 16 21 2.54 2.54 2.72
Total Noncurrent Liabilities		 66 60 55 74 74 76
Long-Term Debt		 52 47 42 62 62 62
Other Noncurrent Operating Liabilities		 14 13 13 12 12 14
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 455 462 463 456 462 465
Total Preferred & Common Equity		 455 462 463 456 462 465
Total Common Equity		 455 462 463 456 462 465
Common Stock		 791 803 812 827 841 851
Retained Earnings		 -333 -338 -347 -370 -378 -386
Accumulated Other Comprehensive Income / (Loss)		 -3.07 -2.61 -2.18 -0.70 -0.57 -0.15

Annual Metrics and Ratios for AtriCure

This table displays calculated financial ratios and metrics derived from AtriCure's official financial filings.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 31.22% 20.75% 19.54% 12.64% 15.40% 14.47% -10.52% 32.83% 20.43% 20.84% 16.55%
EBITDA Growth		 -21.49% -90.49% -9.54% 30.17% 45.50% -191.12% -34.75% 307.87% -143.07% 63.46% -94.95%
EBIT Growth		 -46.59% -69.54% -17.18% 21.70% 30.32% -92.27% -32.98% 223.91% -178.79% 38.17% -51.00%
NOPAT Growth		 -50.22% -63.33% -16.53% 19.78% 31.43% -93.39% -33.55% 277.63% -154.31% 37.47% -49.96%
Net Income Growth		 -41.43% -67.86% -22.51% 19.34% 21.40% -66.50% -36.83% 204.24% -192.56% 34.49% -46.85%
EPS Growth		 -8.93% -59.02% -8.25% 20.95% 25.30% -51.61% -21.28% 195.61% -193.58% 35.29% -43.94%
Operating Cash Flow Growth		 -313.63% 63.69% -92.80% 40.84% 53.37% -279.07% -25.67% 30.65% -60.67% 120.25% 172.17%
Free Cash Flow Firm Growth		 29.86% -270.02% 79.19% 12.00% -1.93% -253.63% 66.43% -86.00% -40.11% 15.73% 29.37%
Invested Capital Growth		 42.60% 147.48% 1.11% 2.03% 5.59% 29.85% -2.62% 46.55% 11.10% 10.24% 2.78%
Revenue Q/Q Growth		 7.54% 5.23% 3.53% 2.89% 3.51% 3.79% -1.71% 5.99% 4.69% 4.86% 3.96%
EBITDA Q/Q Growth		 2.96% -29.98% 11.68% 27.31% -9.47% -100.14% -5.86% 8.69% 22.25% -48.38% -39.23%
EBIT Q/Q Growth		 -3.35% -24.58% 7.49% 19.47% -3.33% -60.68% -5.23% 9.46% 16.92% -21.57% -18.84%
NOPAT Q/Q Growth		 0.36% -28.04% 8.61% 18.21% -2.83% -62.34% -5.18% 10.11% 16.39% -20.46% -17.14%
Net Income Q/Q Growth		 -2.30% -25.74% 6.42% 18.35% -4.19% -56.22% -5.40% 10.62% 17.08% -22.64% -14.85%
EPS Q/Q Growth		 8.96% -25.97% 9.48% 18.63% 0.00% -59.32% 1.72% 13.54% 15.00% -20.00% -14.46%
Operating Cash Flow Q/Q Growth		 4.64% -35.79% 24.25% 7.90% -14.97% -39.96% 27.36% -36.07% -1.17% 796.80% 17.37%
Free Cash Flow Firm Q/Q Growth		 55.73% -659.43% 80.63% -3.25% 13.49% -10.57% 14.18% 8.93% -122.20% 85.78% 19.74%
Invested Capital Q/Q Growth		 -3.58% 137.56% -2.55% 0.22% -1.86% -2.19% -4.67% -3.10% 0.00% 5.39% 1.61%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 70.50% 71.58% 71.63% 72.21% 72.97% 73.80% 72.29% 75.04% 74.44% 75.23% 74.69%
EBITDA Margin		 -9.85% -15.54% -14.24% -8.83% -4.17% -10.60% -15.96% 24.98% -8.93% -2.70% -4.52%
Operating Margin		 -15.23% -20.59% -20.07% -14.30% -8.49% -14.35% -21.42% 20.12% -12.92% -6.68% -8.60%
EBIT Margin		 -14.86% -20.87% -20.45% -14.22% -8.59% -14.42% -21.43% 19.99% -13.08% -6.69% -8.67%
Profit (Net Income) Margin		 -15.09% -20.97% -21.49% -15.39% -10.48% -15.25% -23.32% 18.30% -14.06% -7.62% -9.61%
Tax Burden Percent		 100.20% 100.13% 100.12% 100.05% 101.08% 100.57% 100.24% 99.63% 100.58% 101.98% 102.34%
Interest Burden Percent		 101.31% 100.38% 104.96% 108.20% 120.80% 105.15% 108.55% 91.88% 106.93% 111.73% 108.27%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.37% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -21.01% -16.80% -13.67% -10.80% -7.13% -11.68% -13.99% 20.43% -8.84% -5.00% -7.05%
ROIC Less NNEP Spread (ROIC-NNEP)		 -11.11% 0.81% 50.02% 318.92% 17.51% 12.40% 1.85% 23.11% 3.69% 8.42% 18.20%
Return on Net Nonoperating Assets (RNNOA)		 5.21% -0.25% -5.10% -5.52% -3.17% -2.49% -0.61% -9.22% -1.04% -1.60% -2.60%
Return on Equity (ROE)		 -15.80% -17.05% -18.78% -16.32% -10.30% -14.17% -14.60% 11.20% -9.88% -6.60% -9.64%
Cash Return on Invested Capital (CROIC)		 -56.13% -101.69% -14.78% -12.80% -12.57% -37.65% -11.34% -17.33% -19.35% -14.74% -9.79%
Operating Return on Assets (OROA)		 -11.81% -12.55% -11.55% -9.13% -5.54% -7.28% -6.96% 8.25% -7.20% -4.45% -6.60%
Return on Assets (ROA)		 -11.99% -12.61% -12.13% -9.88% -6.77% -7.70% -7.57% 7.55% -7.74% -5.08% -7.31%
Return on Common Equity (ROCE)		 -15.80% -17.05% -18.78% -16.32% -10.30% -14.17% -14.60% 11.20% -9.88% -6.60% -9.64%
Return on Equity Simple (ROE_SIMPLE)		 -12.23% -14.58% -19.79% -16.69% -8.48% -14.23% -11.68% 10.38% -10.17% -6.53% -9.70%
Net Operating Profit after Tax (NOPAT)		 -11 -19 -22 -17 -12 -23 -31 55 -30 -19 -28
NOPAT Margin		 -10.66% -14.41% -14.05% -10.01% -5.95% -10.05% -14.99% 20.05% -9.04% -4.68% -6.02%
Net Nonoperating Expense Percent (NNEP)		 -9.90% -17.62% -63.69% -329.71% -24.64% -24.08% -15.84% -2.68% -12.53% -13.41% -25.25%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -5.65% -3.53% -5.33%
Cost of Revenue to Revenue		 29.50% 28.42% 28.37% 27.79% 27.03% 26.20% 27.71% 24.96% 25.56% 24.77% 25.31%
SG&A Expenses to Revenue		 68.41% 72.33% 68.61% 66.96% 64.24% 72.42% 73.03% 74.60% 70.00% 63.40% 62.62%
R&D to Revenue		 17.31% 19.84% 23.10% 19.54% 17.22% 17.86% 20.85% 17.68% 17.35% 18.51% 20.67%
Operating Expenses to Revenue		 85.72% 92.17% 91.70% 86.51% 81.46% 88.15% 93.71% 54.92% 87.36% 81.92% 83.29%
Earnings before Interest and Taxes (EBIT)		 -16 -27 -32 -25 -17 -33 -44 55 -43 -27 -40
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -11 -20 -22 -15 -8.40 -24 -33 69 -30 -11 -21
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 4.14 3.87 3.86 3.90 4.73 5.20 6.08 6.60 4.51 3.63 3.23
Price to Tangible Book Value (P/TBV)		 6.21 26.14 58.85 122.22 12.43 0.00 50.72 15.50 11.28 10.10 8.78
Price to Revenue (P/Rev)		 5.10 5.57 4.19 3.60 5.85 5.57 12.14 11.64 6.24 4.24 3.20
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 63.62 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1.57% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 7.49 4.38 4.01 3.86 6.38 5.63 10.59 9.47 5.51 4.13 3.55
Enterprise Value to Revenue (EV/Rev)		 4.47 5.35 4.14 3.61 5.47 5.47 11.20 11.05 5.93 4.05 3.08
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 44.22 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 55.25 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 55.09 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 360.70 117.33
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.08 0.23 0.23 0.19 0.29 0.16 0.12 0.16 0.14 0.14
Long-Term Debt to Equity		 0.00 0.07 0.22 0.23 0.19 0.29 0.16 0.12 0.14 0.13 0.13
Financial Leverage		 -0.47 -0.30 -0.10 -0.02 -0.18 -0.20 -0.33 -0.40 -0.28 -0.19 -0.14
Leverage Ratio		 1.32 1.35 1.55 1.65 1.52 1.84 1.93 1.48 1.28 1.30 1.32
Compound Leverage Factor		 1.34 1.36 1.62 1.79 1.84 1.94 2.09 1.36 1.37 1.45 1.43
Debt to Total Capital		 0.06% 7.05% 18.76% 18.61% 16.07% 22.40% 13.51% 10.99% 13.53% 11.93% 12.30%
Short-Term Debt to Total Capital		 0.00% 0.22% 0.81% 0.00% 0.00% 0.00% 0.00% 0.00% 1.04% 0.48% 0.53%
Long-Term Debt to Total Capital		 0.06% 6.83% 17.94% 18.61% 16.07% 22.40% 13.51% 10.99% 12.49% 11.45% 11.77%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 99.94% 92.95% 81.24% 81.39% 83.93% 77.60% 86.49% 89.01% 86.47% 88.07% 87.70%
Debt to EBITDA		 -0.01 -0.70 -1.76 -2.39 -5.68 -2.92 -1.95 0.87 -2.42 -5.85 -3.08
Net Debt to EBITDA		 6.47 1.40 0.37 -0.16 9.12 0.94 5.89 -2.39 3.43 6.88 2.76
Long-Term Debt to EBITDA		 -0.01 -0.68 -1.68 -2.39 -5.68 -2.92 -1.95 0.87 -2.24 -5.62 -2.94
Debt to NOPAT		 -0.01 -0.76 -1.78 -2.11 -3.98 -3.08 -2.08 1.09 -2.39 -3.38 -2.31
Net Debt to NOPAT		 5.98 1.50 0.37 -0.14 6.39 0.99 6.27 -2.98 3.39 3.97 2.07
Long-Term Debt to NOPAT		 -0.01 -0.73 -1.71 -2.11 -3.98 -3.08 -2.08 1.09 -2.21 -3.24 -2.21
Altman Z-Score		 12.36 4.51 3.04 2.93 6.48 2.19 4.85 14.94 9.47 6.94 6.03
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.65 2.37 2.97 2.58 4.34 2.87 6.24 3.47 3.69 3.57 3.65
Quick Ratio		 3.01 1.71 2.26 1.80 3.72 2.20 5.44 2.69 2.81 2.55 2.49
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -31 -113 -24 -21 -21 -75 -25 -47 -65 -55 -39
Operating Cash Flow to CapEx		 -397.72% -58.33% -196.63% -140.10% -67.22% -130.21% -377.81% -141.29% -131.16% 37.37% 106.73%
Free Cash Flow to Firm to Interest Expense		 -100.30 -387.66 -13.08 -9.16 -4.59 -18.18 -5.14 -9.49 -13.11 -7.96 -5.01
Operating Cash Flow to Interest Expense		 -70.82 -26.86 -8.39 -3.95 -0.91 -3.85 -4.07 -2.80 -4.44 0.65 1.57
Operating Cash Flow Less CapEx to Interest Expense		 -88.63 -72.90 -12.66 -6.77 -2.25 -6.80 -5.14 -4.79 -7.83 -1.09 0.10
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.79 0.60 0.56 0.64 0.65 0.50 0.32 0.41 0.55 0.67 0.76
Accounts Receivable Turnover		 6.89 7.02 7.66 7.91 8.35 8.67 8.07 9.77 8.73 8.39 8.25
Inventory Turnover		 2.59 2.31 2.49 2.42 2.43 2.33 1.78 1.85 1.99 1.74 1.64
Fixed Asset Turnover		 12.50 6.06 5.06 5.95 7.22 7.73 6.78 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 3.91 3.62 3.76 4.20 4.94 4.92 4.13 4.37 4.39 4.19 4.50
Days Sales Outstanding (DSO)		 53.01 51.99 47.66 46.15 43.70 42.10 45.24 37.37 41.82 43.51 44.26
Days Inventory Outstanding (DIO)		 140.86 157.94 146.47 150.77 150.44 156.62 205.52 197.22 183.49 210.10 221.93
Days Payable Outstanding (DPO)		 93.40 100.78 97.11 86.84 73.96 74.26 88.29 83.52 83.20 87.22 81.17
Cash Conversion Cycle (CCC)		 100.47 109.15 97.01 110.07 120.18 124.46 162.46 151.07 142.11 166.40 185.02
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 64 159 160 164 173 224 218 320 356 392 403
Invested Capital Turnover		 1.97 1.17 0.97 1.08 1.20 1.16 0.93 1.02 0.98 1.07 1.17
Increase / (Decrease) in Invested Capital		 19 94 1.77 3.25 9.15 52 -5.87 102 36 36 11
Enterprise Value (EV)		 480 695 642 631 1,102 1,263 2,312 3,030 1,959 1,617 1,432
Market Capitalization		 548 723 651 629 1,179 1,286 2,506 3,194 2,060 1,692 1,490
Book Value per Share		 $4.82 $5.79 $5.07 $4.68 $6.47 $6.25 $9.16 $10.53 $9.99 $9.84 $9.46
Tangible Book Value per Share		 $3.21 $0.86 $0.33 $0.15 $2.46 ($2.97) $1.10 $4.48 $3.99 $3.53 $3.48
Total Capital		 133 201 207 198 297 319 477 543 528 529 526
Total Debt		 0.07 14 39 37 48 71 64 60 71 63 65
Total Long-Term Debt		 0.07 14 37 37 48 71 64 60 66 61 62
Net Debt		 -68 -28 -8.12 2.41 -77 -23 -194 -164 -101 -74 -58
Capital Expenditures (CapEx)		 5.43 13 7.69 6.38 6.21 12 5.26 9.75 17 12 11
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 8.22 9.04 15 16 10 11 13 21 41 57 74
Debt-free Net Working Capital (DFNWC)		 68 44 59 50 134 93 258 140 162 194 197
Net Working Capital (NWC)		 68 43 57 50 134 93 258 140 157 192 194
Net Nonoperating Expense (NNE)		 4.76 8.51 12 9.41 9.15 12 17 4.80 17 12 17
Net Nonoperating Obligations (NNO)		 -68 -28 -8.12 2.41 -77 -23 -194 -164 -101 -74 -58
Total Depreciation and Amortization (D&A)		 5.39 6.92 9.64 9.42 8.91 8.82 11 14 14 16 19
Debt-free, Cash-free Net Working Capital to Revenue		 7.65% 6.96% 9.39% 9.10% 4.99% 4.96% 6.48% 7.49% 12.46% 14.26% 16.01%
Debt-free Net Working Capital to Revenue		 63.16% 33.61% 37.77% 28.82% 66.69% 40.40% 124.73% 50.90% 49.12% 48.64% 42.38%
Net Working Capital to Revenue		 63.16% 33.27% 36.68% 28.82% 66.69% 40.40% 124.73% 50.90% 47.47% 48.01% 41.78%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.61) ($0.97) ($1.05) ($0.83) ($0.62) ($0.94) ($1.14) $1.11 ($1.02) ($0.66) ($0.95)
Adjusted Weighted Average Basic Shares Outstanding		 27.59M 32.27M 33.34M 34.56M 38.61M 40.05M 45.57M 45.07M 45.74M 46.31M 46.97M
Adjusted Diluted Earnings per Share		 ($0.61) ($0.97) ($1.05) ($0.83) ($0.62) ($0.94) ($1.14) $1.09 ($1.02) ($0.66) ($0.95)
Adjusted Weighted Average Diluted Shares Outstanding		 27.59M 32.27M 33.34M 34.56M 38.61M 40.05M 45.57M 46.04M 45.74M 46.31M 46.97M
Adjusted Basic & Diluted Earnings per Share		 ($0.61) ($0.97) ($1.05) ($0.83) ($0.62) ($0.94) ($1.14) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 26.37M 28.06M 31.61M 32.39M 34.09M 37.59M 42.13M 46.03M 93.14M 95.18M 48.88M
Normalized Net Operating Profit after Tax (NOPAT)		 -11 -19 -22 -17 -12 -27 -31 -47 -30 -19 -28
Normalized NOPAT Margin		 -10.66% -14.41% -14.05% -10.01% -5.95% -11.54% -15.11% -17.18% -9.04% -4.68% -6.02%
Pre Tax Income Margin		 -15.06% -20.94% -21.47% -15.38% -10.37% -15.16% -23.26% 18.37% -13.98% -7.48% -9.39%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -52.36 -92.72 -17.61 -10.97 -3.76 -8.10 -9.06 11.15 -8.67 -3.86 -5.19
NOPAT to Interest Expense		 -37.55 -64.05 -12.10 -7.72 -2.60 -5.64 -6.34 11.18 -5.99 -2.70 -3.61
EBIT Less CapEx to Interest Expense		 -70.16 -138.76 -21.88 -13.79 -5.10 -11.05 -10.14 9.17 -12.05 -5.59 -6.66
NOPAT Less CapEx to Interest Expense		 -55.35 -110.10 -16.37 -10.54 -3.95 -8.59 -7.42 9.20 -9.38 -4.43 -5.08
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -0.24% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for AtriCure

This table displays calculated financial ratios and metrics derived from AtriCure's official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 18.15% 20.23% 25.37% 19.39% 18.07% 21.03% 16.43% 15.21% 17.93% 16.64%
EBITDA Growth		 -107.69% 92.64% 77.51% 95.72% 52.31% -523.99% -160.57% -479.55% 44.11% -141.46%
EBIT Growth		 -111.45% 69.18% 60.42% 69.01% 27.69% -120.89% -95.12% -67.33% 12.34% -73.87%
NOPAT Growth		 -107.61% 66.92% 59.14% 69.66% 24.56% -109.57% -88.81% -72.97% 8.46% -67.55%
Net Income Growth		 -112.64% 69.65% 57.35% 65.51% 26.21% -134.75% -104.90% -56.47% 13.27% -59.04%
EPS Growth		 -112.80% 64.29% 57.58% 65.63% 25.93% -110.00% -100.00% -54.55% 15.00% -57.14%
Operating Cash Flow Growth		 -668.97% -84.72% 83.44% -28.80% 185.31% 8,660.87% -415.22% 145.10% 1,214.32% 44.81%
Free Cash Flow Firm Growth		 12,696.25% 65.21% 100.82% 76.13% -216.99% -10.62% -6,331.09% -17.16% 92.12% 50.40%
Invested Capital Growth		 0.00% 11.10% -1.50% 9.12% 0.00% 10.24% 19.36% 9.36% 6.61% 2.78%
Revenue Q/Q Growth		 -1.52% 5.74% 6.21% 7.94% -2.60% 8.40% 2.17% 6.81% -0.31% 7.22%
EBITDA Q/Q Growth		 23.49% 91.47% -258.27% 81.70% -752.73% -11.59% -49.61% 59.29% 17.76% -382.12%
EBIT Q/Q Growth		 18.15% 65.22% -43.80% 24.30% -91.02% -6.23% -27.02% 35.09% -0.07% -110.71%
NOPAT Q/Q Growth		 21.50% 61.43% -39.80% 28.33% -95.20% -7.16% -25.95% 34.34% -3.31% -96.12%
Net Income Q/Q Growth		 17.31% 66.02% -55.30% 20.97% -76.92% -8.11% -35.55% 39.65% 1.94% -98.24%
EPS Q/Q Growth		 15.63% 62.96% -40.00% 21.43% -81.82% -5.00% -33.33% 39.29% 0.00% -94.12%
Operating Cash Flow Q/Q Growth		 -142.18% 102.58% -8,967.39% 173.82% -49.45% 164.78% -621.49% 135.12% 171.06% -70.83%
Free Cash Flow Firm Q/Q Growth		 325.06% -111.90% 103.11% -2,962.90% -1,003.26% 88.75% -86.44% 46.17% 25.78% 29.19%
Invested Capital Q/Q Growth		 -100.00% 0.00% -2.87% 8.54% -0.77% 5.39% 5.84% -0.56% -3.26% 1.61%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 74.13% 73.97% 74.45% 76.38% 75.15% 74.91% 74.66% 74.69% 74.88% 74.53%
EBITDA Margin		 -9.45% -0.76% -2.57% -0.44% -3.82% -3.93% -5.75% -2.19% -1.81% -8.14%
Operating Margin		 -12.88% -4.70% -6.18% -4.11% -8.23% -8.14% -10.03% -6.17% -6.39% -11.69%
EBIT Margin		 -13.54% -4.45% -6.03% -4.23% -8.29% -8.13% -10.10% -6.14% -6.16% -12.11%
Profit (Net Income) Margin		 -14.74% -4.74% -6.93% -5.07% -9.21% -9.19% -12.19% -6.89% -6.78% -12.53%
Tax Burden Percent		 100.38% 102.99% 101.22% 101.85% 100.52% 103.96% 101.40% 103.26% 104.28% 101.74%
Interest Burden Percent		 108.46% 103.29% 113.50% 117.76% 110.51% 108.74% 118.97% 108.61% 105.40% 101.64%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% -3.22% -4.35% -2.93% -11.79% -6.08% -7.68% -4.73% -5.21% -9.58%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -2.25% -2.15% -0.72% -4.33% -1.84% -0.36% -0.45% -1.86% -1.40%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.63% 0.52% 0.16% 0.85% 0.35% 0.06% 0.07% 0.32% 0.20%
Return on Equity (ROE)		 0.00% -2.58% -3.82% -2.77% -10.94% -5.73% -7.62% -4.66% -4.89% -9.38%
Cash Return on Invested Capital (CROIC)		 0.00% -19.35% -5.39% -13.55% -208.34% -14.74% -23.53% -15.16% -12.62% -9.79%
Operating Return on Assets (OROA)		 0.00% -2.45% -3.61% -2.62% -5.26% -5.41% -7.13% -4.43% -4.54% -9.22%
Return on Assets (ROA)		 0.00% -2.61% -4.14% -3.14% -5.84% -6.12% -8.60% -4.97% -4.99% -9.53%
Return on Common Equity (ROCE)		 0.00% -2.58% -3.82% -2.77% -10.94% -5.73% -7.62% -4.66% -4.89% -9.38%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% -8.30% -6.06% -5.36% 0.00% -8.16% -8.68% -8.37% 0.00%
Net Operating Profit after Tax (NOPAT)		 -7.51 -2.90 -4.05 -2.90 -5.66 -6.07 -7.64 -5.02 -5.18 -10
NOPAT Margin		 -9.02% -3.29% -4.33% -2.87% -5.76% -5.70% -7.02% -4.32% -4.47% -8.18%
Net Nonoperating Expense Percent (NNEP)		 0.00% -0.96% -2.19% -2.21% -7.47% -4.25% -7.33% -4.28% -3.35% -8.17%
Return On Investment Capital (ROIC_SIMPLE)		 - -0.55% - - - -1.15% - - - -1.93%
Cost of Revenue to Revenue		 25.87% 26.03% 25.55% 23.62% 24.85% 25.09% 25.34% 25.31% 25.12% 25.47%
SG&A Expenses to Revenue		 68.79% 63.05% 64.24% 63.20% 62.68% 63.53% 66.46% 63.30% 63.19% 58.08%
R&D to Revenue		 18.22% 15.62% 16.39% 17.28% 20.71% 19.52% 18.23% 17.56% 18.08% 28.13%
Operating Expenses to Revenue		 87.01% 78.67% 80.64% 80.48% 83.38% 83.05% 84.69% 80.86% 81.27% 86.21%
Earnings before Interest and Taxes (EBIT)		 -11 -3.92 -5.64 -4.27 -8.15 -8.66 -11 -7.14 -7.15 -15
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -7.87 -0.67 -2.40 -0.44 -3.75 -4.19 -6.26 -2.55 -2.10 -10
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 4.51 4.24 5.04 4.48 3.63 3.16 2.38 2.94 3.23
Price to Tangible Book Value (P/TBV)		 0.00 11.28 10.64 14.55 12.77 10.10 9.04 6.59 7.94 8.78
Price to Revenue (P/Rev)		 5.75 6.24 5.53 6.38 5.45 4.24 3.48 2.56 3.05 3.20
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 5.51 5.27 5.99 5.33 4.13 3.39 2.56 3.27 3.55
Enterprise Value to Revenue (EV/Rev)		 0.00 5.93 5.21 6.14 5.21 4.05 3.37 2.44 2.90 3.08
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 3,966.13 360.70 0.00 0.00 124.74 117.33
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.16 0.11 0.10 0.09 0.14 0.14 0.13 0.13 0.14
Long-Term Debt to Equity		 0.00 0.14 0.11 0.10 0.09 0.13 0.14 0.13 0.13 0.13
Financial Leverage		 0.00 -0.28 -0.24 -0.22 -0.20 -0.19 -0.17 -0.15 -0.17 -0.14
Leverage Ratio		 0.00 1.28 1.27 1.29 1.30 1.30 1.29 1.29 1.31 1.32
Compound Leverage Factor		 0.00 1.32 1.44 1.51 1.43 1.41 1.53 1.40 1.38 1.34
Debt to Total Capital		 0.00% 13.53% 10.25% 9.23% 8.35% 11.93% 11.94% 11.81% 11.74% 12.30%
Short-Term Debt to Total Capital		 0.00% 1.04% 0.00% 0.00% 0.00% 0.48% 0.00% 0.00% 0.00% 0.53%
Long-Term Debt to Total Capital		 0.00% 12.49% 10.25% 9.23% 8.35% 11.45% 11.94% 11.81% 11.74% 11.77%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 86.47% 89.75% 90.77% 91.65% 88.07% 88.06% 88.19% 88.26% 87.70%
Debt to EBITDA		 0.00 -2.42 -2.45 -4.13 -5.80 -5.85 -4.22 -3.69 -4.10 -3.08
Net Debt to EBITDA		 0.00 3.43 5.16 7.69 12.50 6.88 3.01 3.11 4.54 2.76
Long-Term Debt to EBITDA		 0.00 -2.24 -2.45 -4.13 -5.80 -5.62 -4.22 -3.69 -4.10 -2.94
Debt to NOPAT		 0.00 -2.39 -2.16 -2.71 -2.72 -3.38 -2.78 -2.54 -2.59 -2.31
Net Debt to NOPAT		 0.00 3.39 4.56 5.05 5.86 3.97 1.98 2.14 2.86 2.07
Long-Term Debt to NOPAT		 0.00 -2.21 -2.16 -2.71 -2.72 -3.24 -2.78 -2.54 -2.59 -2.21
Altman Z-Score		 0.00 9.69 9.16 10.75 9.17 7.03 6.53 5.07 5.65 6.17
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 0.00 3.69 3.82 3.33 3.06 3.57 4.00 4.13 3.62 3.65
Quick Ratio		 0.00 2.81 2.91 2.46 2.24 2.55 2.63 2.77 2.49 2.49
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 323 -38 1.20 -34 -378 -42 -74 -40 -30 -21
Operating Cash Flow to CapEx		 -34.67% 1.10% -163.03% 97.76% 41.93% 144.65% -757.61% 309.56% 554.43% 216.71%
Free Cash Flow to Firm to Interest Expense		 243.80 -24.61 0.73 -19.91 -213.11 -23.63 -24.51 -24.88 -17.85 -14.52
Operating Cash Flow to Interest Expense		 -1.35 0.03 -2.49 1.75 0.86 2.24 -6.92 4.58 12.00 4.02
Operating Cash Flow Less CapEx to Interest Expense		 -5.23 -2.64 -4.02 -0.04 -1.19 0.69 -7.83 3.10 9.84 2.17
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.55 0.60 0.62 0.63 0.67 0.71 0.72 0.74 0.76
Accounts Receivable Turnover		 0.00 8.73 8.07 8.14 7.39 8.39 8.21 8.27 8.41 8.25
Inventory Turnover		 0.00 1.99 1.99 1.91 1.54 1.74 1.70 1.68 1.63 1.64
Fixed Asset Turnover		 0.00 0.00 9.64 9.55 9.20 0.00 10.16 10.40 10.54 0.00
Accounts Payable Turnover		 0.00 4.39 4.07 3.89 3.87 4.19 3.90 4.29 4.01 4.50
Days Sales Outstanding (DSO)		 0.00 41.82 45.21 44.84 49.40 43.51 44.45 44.11 43.40 44.26
Days Inventory Outstanding (DIO)		 0.00 183.49 183.05 191.46 237.65 210.10 214.92 217.78 223.88 221.93
Days Payable Outstanding (DPO)		 0.00 83.20 89.58 93.91 94.23 87.22 93.50 85.00 91.01 81.17
Cash Conversion Cycle (CCC)		 0.00 142.11 138.68 142.39 192.82 166.40 165.87 176.89 176.27 185.02
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 0.00 356 345 375 372 392 412 410 397 403
Invested Capital Turnover		 0.00 0.98 1.00 1.02 2.05 1.07 1.09 1.10 1.16 1.17
Increase / (Decrease) in Invested Capital		 -330 36 -5.24 31 372 36 67 35 25 11
Enterprise Value (EV)		 0.00 1,959 1,821 2,244 1,983 1,617 1,398 1,050 1,297 1,432
Market Capitalization		 1,815 2,060 1,930 2,332 2,074 1,692 1,442 1,102 1,365 1,490
Book Value per Share		 $0.00 $9.99 $9.77 $9.79 $9.77 $9.84 $9.77 $9.55 $9.55 $9.46
Tangible Book Value per Share		 $0.00 $3.99 $3.90 $3.39 $3.43 $3.53 $3.41 $3.45 $3.53 $3.48
Total Capital		 0.00 528 507 509 505 529 518 524 527 526
Total Debt		 0.00 71 52 47 42 63 62 62 62 65
Total Long-Term Debt		 0.00 66 52 47 42 61 62 62 62 62
Net Debt		 0.00 -101 -109 -88 -91 -74 -44 -52 -68 -58
Capital Expenditures (CapEx)		 5.15 4.17 2.50 3.08 3.63 2.79 2.77 2.38 3.61 2.69
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 41 40 40 37 57 78 78 65 74
Debt-free Net Working Capital (DFNWC)		 0.00 162 176 167 170 194 184 192 195 197
Net Working Capital (NWC)		 0.00 157 176 167 170 192 184 192 195 194
Net Nonoperating Expense (NNE)		 4.77 1.27 2.43 2.22 3.39 3.72 5.63 2.99 2.67 5.40
Net Nonoperating Obligations (NNO)		 0.00 -101 -109 -88 -91 -74 -44 -52 -68 -58
Total Depreciation and Amortization (D&A)		 3.40 3.25 3.23 3.83 4.40 4.47 4.74 4.59 5.05 4.95
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 12.46% 11.45% 10.81% 9.76% 14.26% 18.82% 18.05% 14.42% 16.01%
Debt-free Net Working Capital to Revenue		 0.00% 49.12% 50.35% 45.55% 44.70% 48.64% 44.37% 44.57% 43.54% 42.38%
Net Working Capital to Revenue		 0.00% 47.47% 50.35% 45.55% 44.70% 48.01% 44.37% 44.57% 43.54% 41.78%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($0.10) ($0.14) ($0.11) ($0.20) ($0.21) ($0.28) ($0.17) ($0.17) ($0.33)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 45.74M 46.11M 46.27M 46.41M 46.31M 46.72M 46.91M 47.11M 46.97M
Adjusted Diluted Earnings per Share		 $0.00 ($0.10) ($0.14) ($0.11) ($0.20) ($0.21) ($0.28) ($0.17) ($0.17) ($0.33)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 45.74M 46.11M 46.27M 46.41M 46.31M 46.72M 46.91M 47.11M 46.97M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 93.14M 47.24M 47.35M 47.40M 95.18M 48.38M 48.70M 48.75M 48.88M
Normalized Net Operating Profit after Tax (NOPAT)		 -7.51 -2.90 -4.05 -2.90 -5.66 -6.07 -7.64 -5.02 -5.18 -10
Normalized NOPAT Margin		 -9.02% -3.29% -4.33% -2.87% -5.76% -5.70% -7.02% -4.32% -4.47% -8.18%
Pre Tax Income Margin		 -14.69% -4.60% -6.84% -4.98% -9.16% -8.84% -12.02% -6.67% -6.50% -12.31%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 -8.51 -2.51 -3.45 -2.48 -4.60 -4.82 -3.62 -4.43 -4.29 -10.38
NOPAT to Interest Expense		 -5.67 -1.85 -2.47 -1.69 -3.20 -3.37 -2.51 -3.11 -3.11 -7.01
EBIT Less CapEx to Interest Expense		 -12.40 -5.18 -4.97 -4.27 -6.65 -6.37 -4.53 -5.91 -6.45 -12.23
NOPAT Less CapEx to Interest Expense		 -9.56 -4.53 -4.00 -3.48 -5.24 -4.92 -3.43 -4.59 -5.27 -8.86
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About AtriCure's Financials

When does AtriCure's fiscal year end?

According to the most recent income statement we have on file, AtriCure's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has AtriCure's net income changed over the last 10 years?

AtriCure's net income appears to be on an upward trend, with a most recent value of -$44.70 million in 2024, rising from -$16.21 million in 2014. The previous period was -$30.44 million in 2023.

What is AtriCure's operating income?
AtriCure's total operating income in 2024 was -$40.01 million, based on the following breakdown:
  • Total Gross Profit: $347.52 million
  • Total Operating Expenses: $387.54 million
How has AtriCure revenue changed over the last 10 years?

Over the last 10 years, AtriCure's total revenue changed from $107.45 million in 2014 to $465.31 million in 2024, a change of 333.0%.

How much debt does AtriCure have?

AtriCure's total liabilities were at $148.36 million at the end of 2024, a 0.4% increase from 2023, and a 473.6% increase since 2014.

How much cash does AtriCure have?

In the past 10 years, AtriCure's cash and equivalents has ranged from $21.81 million in 2017 to $122.72 million in 2024, and is currently $122.72 million as of their latest financial filing in 2024.

How has AtriCure's book value per share changed over the last 10 years?

Over the last 10 years, AtriCure's book value per share changed from 4.82 in 2014 to 9.46 in 2024, a change of 96.0%.

Remove Ads

Related Companies

This page (NASDAQ:ATRC) was last updated on 4/16/2025 by MarketBeat.com Staff
From Our Partners
This Crypto Is Set to Explode in January
The crypto summit Wall Street wants to stop Learn how to structure your portfolio like the top hedge funds...
Crypto 101 Media | Sponsored
Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...
Porter & Company | Sponsored
Crypto’s crashing…but we’re still profiting
Most traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....
Crypto Swap Profits | Sponsored
Markets in Chaos? Here’s What to Do.
Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...
Investors Alley | Sponsored
Catastrophic
The losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.
InvestorPlace | Sponsored
Trump 2028 could be a “bonanza” for investors
As you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...
Paradigm Press | Sponsored
If Gold Is ‘Stalling,’ Why Are Banks Hoarding Billions In Secret?
Prosperity was something every American family could build, protect, and pass down. Because that's what legacy...
Colonial Metals | Sponsored
Musk’s AI Masterplan – Our #1 AI Stock to Buy Now
Did Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...
Behind the Markets | Sponsored